Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target

<p>Table S1 shows expression of RBPs in an RNA-sequencing data set of human bone marrow hematopoietic stem and progenitor subpopulations.</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Ana Vujovic (15207479) (author)
Άλλοι συγγραφείς:	Laura de Rooij (15207482) (author), Ava Keyvani Chahi (15207485) (author), He Tian Chen (15207488) (author), Brian A. Yee (15207491) (author), Sampath K. Loganathan (15121740) (author), Lina Liu (15207494) (author), Derek C.H. Chan (15207497) (author), Amanda Tajik (15207500) (author), Emily Tsao (15207503) (author), Steven Moreira (14937143) (author), Pratik Joshi (15207506) (author), Joshua Xu (15207509) (author), Nicholas Wong (15207512) (author), Zaldy Balde (15207515) (author), Soheil Jahangiri (15207518) (author), Sasan Zandi (15207521) (author), Stefan Aigner (15207524) (author), John E. Dick (14937554) (author), Mark D. Minden (14961936) (author), Daniel Schramek (15121764) (author), Gene W. Yeo (15207527) (author), Kristin J. Hope (15207530) (author)
Έκδοση:	2025
Θέματα:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Drug Targets Oncoprotein & tumor suppressor drug targets Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Oncogenes & Tumor Suppressors Oncogenes Preclinical Models Xenograft models Small Molecule Agents Stem Cell Biology Cancer stem cells Hematopoiesis
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
ανά: Ana Vujovic (15207479)
Έκδοση: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
ανά: Ana Vujovic (15207479)
Έκδοση: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
ανά: Ana Vujovic (15207479)
Έκδοση: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
ανά: Ana Vujovic (15207479)
Έκδοση: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
ανά: Ana Vujovic (15207479)
Έκδοση: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
ανά: Ana Vujovic (15207479)
Έκδοση: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
ανά: Ana Vujovic (15207479)
Έκδοση: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
ανά: Ana Vujovic (15207479)
Έκδοση: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
ανά: Amir T. Fathi (15313195)
Έκδοση: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
ανά: Amir T. Fathi (15313195)
Έκδοση: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
ανά: Smruthy Sivakumar (15053536)
Έκδοση: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
ανά: Long Jiang (14956159)
Έκδοση: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
ανά: Long Jiang (14956159)
Έκδοση: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
ανά: Long Jiang (14956159)
Έκδοση: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
ανά: Yun-Guang Hong (14960966)
Έκδοση: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
ανά: Yun-Guang Hong (14960966)
Έκδοση: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
ανά: Yun-Guang Hong (14960966)
Έκδοση: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
ανά: Yun-Guang Hong (14960966)
Έκδοση: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
ανά: Yun-Guang Hong (14960966)
Έκδοση: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
ανά: Yun-Guang Hong (14960966)
Έκδοση: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
ανά: Yuanqing Ma (15052437)
Έκδοση: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
ανά: Yuanqing Ma (15052437)
Έκδοση: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
ανά: Yuanqing Ma (15052437)
Έκδοση: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
ανά: Yuanqing Ma (15052437)
Έκδοση: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
ανά: Yuanqing Ma (15052437)
Έκδοση: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
ανά: Yuanqing Ma (15052437)
Έκδοση: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
ανά: Yuanqing Ma (15052437)
Έκδοση: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
ανά: Yuanqing Ma (15052437)
Έκδοση: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
ανά: Feng Wang (44414)
Έκδοση: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
ανά: Feng Wang (44414)
Έκδοση: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
ανά: Feng Wang (44414)
Έκδοση: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
ανά: Feng Wang (44414)
Έκδοση: (2025)

Supplementary Tables S3-5 from Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis
ανά: Nicole Dressel (16918215)
Έκδοση: (2025)

Cannot write session to /tmp/vufind_sessions/sess_oviaoes8vp4atu1nbqj87d4evr